Repligen: Pay

Repligen paid its 5 named executives $16.1M in total in FY2025 (Dec). CEO Olivier Loeillot was paid $6.1M of that.

Pay$100 in the stock at the end of FY22 → $97
CEO pay is from each proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Pay of each named executive

Olivier LoeillotPresident and Chief Executive Officer
FY2025 (Dec)
FY2024 (Dec)
FY2023 (Dec)
3 years
Jason K. GarlandChief Financial Officer
FY2025 (Dec)
FY2024 (Dec)
FY2023 (Dec)
3 years
James BylundChief Operating Officer
FY2025 (Dec)
FY2024 (Dec)
FY2023 (Dec)
FY2022 (Dec)Not disclosed
FY2021 (Dec)Not disclosed
5 years
Ralf KuriyelSenior Vice President, Research and Development
FY2025 (Dec)
FY2024 (Dec)
FY2023 (Dec)
FY2022 (Dec)Not disclosed
FY2021 (Dec)Not disclosed
5 years
Brian DouglassSenior Vice President, Chief Product Officer
FY2025 (Dec)
1 year

CEO pay against the pay peers

In FY2025 (Dec), the median CEO pay of the 6 peers with pay on file was $13.2M. The CEO of Repligen was paid $6.1M, 54% below the median.

  1. 1Halozyme Therapeutics
  2. 2Insulet
  3. 3Natera
  4. 4Medpace Holdings
  5. 5BIO-TECHNE
  6. 6Repligen
  7. 7Bruker
  8. 810x Genomics, Inc.Not disclosed
  9. 9Azenta, Inc.Not disclosed
  10. 10Bio-Rad Laboratories, Inc.Not disclosed
  11. 11Maravai LifeSciences Holdings, Inc.Not disclosed
  12. 12Mesa Laboratories, Inc.Not disclosed
  13. 13NeoGenomics, IncNot disclosed
  14. 14Neogen CorporationNot disclosed
  15. 15NovaCure Limited, Inc.Not disclosed
  16. 16Quanterix CorporationNot disclosed
  17. 17Waters CorporationNot disclosed

Pay of each named executive comes from the Summary Compensation Table of each proxy statement. Realized pay adds the value of options used and stock that vested. CEO pay of each peer comes from its own Pay versus Performance table.